文献速递抗栓抗凝管理

内科患者延长疗程血栓预防的临床聚焦综述

A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
PubMed 文献 · Am J Health Syst Pharm · 2021-01-01

本综述通过MEDLINE检索评估延长疗程血栓预防(EDT)在内科患者中的安全性与有效性。纳入8项荟萃分析和5项随机对照试验,涉及依诺肝素、利伐沙班、阿哌沙班和贝曲沙班。数据显示EDT降低VTE发生率但增加大出血风险且未降低死亡率,支持指南不推荐常规使用EDT。

要点

  • EDT降低VTE发生率但增加大出血风险,未降低死亡率。
  • 指南不推荐多数内科患者常规延长血栓预防。
  • 利伐沙班和贝曲沙班基于APEX和MARINER试验获FDA批准用于EDT。

核心结论

  • 支持内科患者EDT的证据尚不明确,需个体化决策。
  • 证据支持ACCP和ASH指南不推荐多数内科患者常规使用EDT。

研究设计与样本

  • 综述,通过MEDLINE检索评估EDT安全性与有效性的原始研究。
  • 纳入8项荟萃分析和5项随机对照试验,涉及依诺肝素、利伐沙班、阿哌沙班和贝曲沙班。

主要发现

  • EDT降低VTE发生率,但增加大出血风险,且未降低死亡率。
  • 纳入研究在入组标准、EDT策略和患者选择方面存在差异,限制EDT的实践适用性。

关键数值与推荐

  • 指南推荐住院期间对血栓风险增加的患者进行药物性血栓预防,但不推荐出院后延长预防。
  • 利伐沙班和贝曲沙班基于APEX和MARINER试验及MAGELLEN试验事后分析获FDA批准用于EDT。

临床怎么用

  • 临床医生应仔细权衡EDT的风险与获益,直至研究显示更有利的风险获益特征。
  • 对多数内科患者,不常规推荐延长疗程血栓预防。

局限性

  • 纳入研究在入组标准、EDT策略和患者选择方面存在差异。
  • 患者选择的不确定性限制EDT的实践应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This review describes and analyzes literature to provide recommendations for use of extended-duration thromboprophylaxis (EDT) in medically ill patients. SUMMARY: Guidelines recommend pharmacologic thromboprophylaxis for patients at increased thrombosis risk during hospitalization and recommend against extending thromboprophylaxis beyond hospitalization. Despite these recommendations, observational data demonstrate that venous thromboembolism (VTE) risk persists following hospital discharge. A MEDLINE literature search was performed to identify original research evaluating the safety and efficacy of EDT. Eight meta-analyses and 5 randomized controlled trials-each varying in the agents studied (enoxaparin, rivaroxaban, apixaban, and betrixaban)-were selected for inclusion. Collectively, the evaluated data demonstrates that EDT reduces the incidence of VTE at the expense of increasing the risk of major bleeding and without providing mortality reduction. Variations in enrollment criteria, differences in EDT strategies, and uncertainty regarding proper patient selection limit the applicability of EDT in practice. Rivaroxaban and betrixaban gained Food and Drug Administration (FDA) approval on the basis of results of the APEX and MARINER trials and a post hoc analysis of the MAGELLEN trial results. Although a number of agents are FDA approved for use in EDT, clinicians must carefully weigh the risks vs benefits of EDT with these agents until studies demonstrate a more favorable risk-benefit profile. CONCLUSION: Evidence to support EDT in medically ill patients is inconclusive and has highlighted the need for an individualized approach. The reviewed evidence supports guideline recommendations from both the American College of Chest Physicians and the American Society of Hematology that recommend against routine use of EDT in the majority of medically ill patients. Future studies are needed to optimize the risk-benefit profile of EDT and to ensure proper patient selection.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Snoga JL, Benitez RM, Kim S, et al. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients. Am J Health Syst Pharm. 2021. PMID: 33580664. doi:10.1093/ajhp/zxab039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。